Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
May 15 LLY Dow Jones Futures: Dow, S&P 500, Nasdaq Hit Highs, Nvidia Leads 12 New Buys; What To Do Now
May 15 LLY Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
May 15 LLY Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
May 15 PFE Dividend picks by SA analysts: PFE, DVN, SBUX and LOW
May 15 LLY Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
May 15 LLY UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
May 15 LLY Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
May 15 PFE Pfizer: Best Trading Momentum Since 2021 And 6% Yield
May 15 LLY Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
May 15 LLY These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now
May 15 PFE 3 No-Brainer Stocks to Buy With $500 Right Now
May 15 LQDA Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
May 15 UTHR Q1 2024 Liquidia Corp Earnings Call
May 15 LQDA Q1 2024 Liquidia Corp Earnings Call
May 14 LLY Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
May 14 LLY Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs
May 14 ASND US Equity Markets Close Higher Tuesday as Producer Prices Rise
May 14 ASND Ascendis Pharma says FDA has delayed TransCon PTH review
May 14 ASND UPDATE 1-FDA extends review of Ascendis Pharma's hormone disorder therapy
May 14 ASND Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags